CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 291 enrolled
Drug / intervention
V120083 +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03028870
NCT03028870Phase 2Completed

A Phase 2a, Multicenter, Randomized, Double-blind, Placebo-controlled and Active-controlled, Parallel-group Study Evaluating the Analgesic Efficacy and Safety of V120083 in Subjects With Moderate to Severe Chronic Pain Due to Osteoarthritis of the Knee

Purdue Pharma LP·interventional·Posted Jan 23, 2017·Updated Feb 12, 2019

In Brief

A Phase 2 clinical trial evaluating V120083, Naproxen, and 1 other intervention for Osteo Arthritis Knee. Completed, enrolled 291 participants across 30 sites.

Detailed Summary

The purpose of this study is to evaluate the analgesic efficacy of V120083 twice daily compared to placebo in subjects with moderate to severe chronic pain due to OA of the knee.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
CollaboratorsShionogi

Timeline

Phase 2CompletedFinished
2017201820192020202120222023202420252026
First PostedJan 23, 2017
Enrollment StartMar 14, 2017
Primary CompletionNov 10, 2017
Study CompletionNov 21, 2017
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 9.4 years ago

Interventions

V120083drug

Capsules

Naproxendrug

Capsules

Placebodrug

Capsules to match V120083 and/or naproxen